433967-28-3

Basic information

• Product Name: VU 0357121
• Synonyms: VU 0357121;BenzaMide, 4-butoxy-N-(2,4-difluorophenyl)-;4-Butoxy-N-(2,4-difluorophenyl)benzamide;VU0357121/VU-0357121
• CAS NO: 433967-28-3
• Molecular Formula: C17H17F2NO2
• Molecular Weight: 305.3191864
• Product Categories: Inhibitors
• Mol File: 433967-28-3.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 338.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.220
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥18mg/mL
• PKA: 11.74±0.70(Predicted)
• CAS DataBase Reference: VU 0357121(CAS DataBase Reference)
• NIST Chemistry Reference: VU 0357121(433967-28-3)
• EPA Substance Registry System: VU 0357121(433967-28-3)

Safety Data

• Hazard Codes: N
• Statements: 50/53
• Safety Statements: 60-61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 433967-28-3(Hazardous Substances Data)

Usage

Description

VU 0357121 is a compound that acts as an allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5). It binds to an allosteric site on mGlu5, which is distinct from the site targeted by CPPHA, but shares a functional interaction with the MPEP site. This unique binding profile allows VU 0357121 to modulate the activity of mGlu5 in a distinct manner, making it a promising candidate for various therapeutic applications.

Uses

Used in Pharmaceutical Industry:
VU 0357121 is used as a therapeutic agent for the treatment of neurological disorders and cognitive impairments. Its ability to modulate mGlu5 activity makes it a potential candidate for the treatment of conditions such as schizophrenia, Alzheimer's disease, and Fragile X syndrome. By selectively targeting the mGlu5 receptor, VU 0357121 may offer improved efficacy and reduced side effects compared to traditional treatments.
Used in Research Applications:
VU 0357121 is used as a research tool for studying the role of mGlu5 in various physiological and pathological processes. Its unique binding profile allows researchers to investigate the specific functions of mGlu5 and its interactions with other signaling pathways. This can help in understanding the underlying mechanisms of neurological disorders and identifying potential therapeutic targets.
Used in Drug Discovery and Development:
VU 0357121 serves as a lead compound for the development of novel mGlu5 modulators with improved pharmacological properties. Its distinct binding profile and functional interaction with the MPEP site provide a foundation for designing new compounds with enhanced selectivity, potency, and safety profiles. These next-generation mGlu5 modulators may offer more effective treatments for neurological disorders and cognitive impairments.